Biologics Safety Testing Market

The biologics safety testing market is projected to reach USD 9.66 billion by 2031 from USD 5.57 billion in 2026, at a CAGR of 11.6%. The growth of the biologics safety testing market is driven by the expanding biologics and biosimilars pipeline, the expansion of CDMOs, and the structural shift toward outsourced testing. Additionally, the growth of advanced modalities such as cell & gene therapies and mRNA products is expected to support market growth.

The global biologics safety testing market is consolidated, with top players such as Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Charles River Laboratories (US), Laboratory Corporation of America Holdings (US), and Merck KGaA (Germany) leading the market. The market players have adopted various strategies, such as approvals and launches of new products and services, acquisitions, agreements, collaborations, partnerships, and geographical expansions, to strengthen their position in the global biologics safety testing market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a top participant in the biologics safety testing market, offering a comprehensive portfolio of assays, kits, reagents, and instruments for sterility, endotoxin, mycoplasma, bioburden, and viral testing. The company supports pharmaceutical and biotechnology firms across development, validation, and commercial manufacturing through its global infrastructure, integrated solutions, and continued investments in advanced biologics and laboratory technologies.

F. Hoffmann-La Roche Ltd (Switzerland)

Roche is a major player in the biologics safety testing market, supported by its diagnostics and life sciences divisions. The company provides instruments, assays, and reagents for molecular and microbial testing, including pathogen detection and quality control. Its strong focus on innovation, automation, and integrated diagnostic solutions supports biologics development and manufacturing, particularly in areas such as infectious disease testing and advanced biologics.

Charles River Laboratories (US)

Charles River Laboratories is a leading provider in the biologics safety testing market, offering outsourced services such as endotoxin, sterility, mycoplasma, bioburden, and viral safety testing. The company supports pharmaceutical and biotechnology clients across development and manufacturing through its global laboratory network, integrated service capabilities, and focus on rapid microbiological methods, helping improve turnaround times and ensure regulatory compliance.

Laboratory Corporation of America Holdings (US)

Laboratory Corporation of America Holdings is a key player in the biologics safety testing market, offering analytical and microbiological testing services that support drug development and manufacturing. Its product portfolio includes sterility, endotoxin, mycoplasma, and microbial testing, backed by a global laboratory network. The company focuses on integrated laboratory services and scalable solutions, enabling pharmaceutical and biotechnology firms to meet regulatory requirements and optimize development timelines.

Related Reports:

Biologics Safety Testing Market by Product (Kits, Reagents, Instruments), Services, Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden), Product & Services by Application (Vaccines, mAbs, CGT), End User, Competition, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]